VYNE Therapeutics Inc. (VYNE)
Market Cap | 30.36M |
Revenue (ttm) | 423,000 |
Net Income (ttm) | -29.08M |
Shares Out | 14.53M |
EPS (ttm) | -1.21 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 12,830 |
Open | 2.130 |
Previous Close | 2.100 |
Day's Range | 2.010 - 2.130 |
52-Week Range | 1.570 - 6.789 |
Beta | 1.46 |
Analysts | Strong Buy |
Price Target | 5.75 (+175.12%) |
Earnings Date | Aug 12, 2024 |
About VYNE
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company w... [Read more]
Financial Performance
In 2023, VYNE's revenue was $424,000, a decrease of -11.11% compared to the previous year's $477,000. Losses were -$28.60 million, 23.2% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for VYNE stock is "Strong Buy" and the 12-month stock price forecast is $5.75.
News
![](https://cdn.snapi.dev/images/v1/r/l/press3-2497142.jpg)
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
![](https://cdn.snapi.dev/images/v1/k/p/press19-2477757.jpg)
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line ...
![](https://cdn.snapi.dev/images/v1/5/w/press17-2420653.jpg)
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
BRIDGEWATER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innov...
![](https://cdn.snapi.dev/images/v1/z/a/press6-2411766.jpg)
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic mode...
![](https://cdn.snapi.dev/images/v1/o/y/press16-2402479.jpg)
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and d...
![](https://cdn.snapi.dev/images/v1/m/e/conf19-2330719.jpg)
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inn...
![](https://cdn.snapi.dev/images/v1/j/g/press17-2300865.jpg)
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inno...
![](https://cdn.snapi.dev/images/v1/x/d/conf7-2295591.jpg)
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
![](https://cdn.snapi.dev/images/v1/y/y/press13-2285691.jpg)
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and...
![](https://cdn.snapi.dev/images/v1/s/k/image23-2230177.jpeg)
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/m/u/press5-2223829.jpg)
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
![](https://cdn.snapi.dev/images/v1/y/m/press10-2214516.jpg)
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
Menlo Ventures Raises $1.35B for AI Investments
Menlo Ventures Partner Matt Murphy joins Caroline Hyde and Ed Ludlow to discuss the firm's latest funding to focus on nascent AI startups and early-stage investments, and explains why he sees generati...
![](https://cdn.snapi.dev/images/v1/u/c/press5-2154304.jpg)
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025
![](https://cdn.snapi.dev/images/v1/k/8/press6-2143767.jpg)
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE's clinical development plans
![](https://cdn.snapi.dev/images/v1/w/r/press5-2134305.jpg)
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025 Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025
![](https://cdn.snapi.dev/images/v1/c/g/press3-2127576.jpg)
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
![](https://cdn.snapi.dev/images/v1/m/r/press20-2127545.jpg)
VYNE Therapeutics Announces Private Placement of $88 Million
Transaction provides $88 million to fund VYNE's clinical development programs for VYN201 and VYN202 through the end of 2025 Transaction provides $88 million to fund VYNE's clinical development program...
![](https://cdn.snapi.dev/images/v1/t/w/press12-2127509.jpg)
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
![](https://cdn.snapi.dev/images/v1/m/q/conf15-2051126.jpg)
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inn...
![](https://cdn.snapi.dev/images/v1/p/f/press18-2021349.jpg)
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023
![](https://cdn.snapi.dev/images/v1/u/q/press8-1896991.jpg)
VYNE Therapeutics to Attend BIO International Convention
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innov...
![](https://cdn.snapi.dev/images/v1/d/5/press12-1886147.jpg)
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023
![](https://cdn.snapi.dev/images/v1/n/q/press11-1862852.jpg)
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development
![](https://cdn.snapi.dev/images/v1/n/4/press19-1843327.jpg)
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and...